

## ABSTRACT

Obtaining the crystal of 4,6-dimethyl-4'-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]nicotinamide having  
5 excellent activity of inhibiting  $\text{Ca}^{2+}$  release-activated  $\text{Ca}^{2+}$   
channel and suppressing IL-2 production to find that the  
compound includes the presence of two types of polymorphic  
crystals and that any of the crystals is preferable as a  
raw material for producing pharmaceutical compositions.

10